Adams gets outperform rating from RBC

RBC Capital Markets analyst Ken Trbovich gave Adams Respiratory Therapeutics Inc. an outperform, above average risk, rating on news that IRI data, which excludes Wal-mart, shows the cough and cold season off to an early start this year. Category sales of both cough/cold/allergy tablets and cough syrups are up 13% in the four weeks ended Oct. 8. According to the analyst, Adams sales of the Mucinex family of products grew 58% to $15.8 million in the four week period, from $9.9 million in the comparable period last year. Shares of the Chester, N.J.-based pharmaceutical company were up 99 cents, or 2.40%, at $42.20. (Nasdaq: ARXT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.